{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:38:09Z","timestamp":1792791489112,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000735","name":"University of Cambridge","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018956","name":"NIHR Cambridge Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.clinme.2025.100520","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T16:14:02Z","timestamp":1760804042000},"page":"100520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["The changing landscape of HIV epidemiology and management"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3330-353X","authenticated-orcid":false,"given":"William L.","family":"Hamilton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sani H.","family":"Aliyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinme.2025.100520_bib0001","unstructured":"UNAIDS. 2024 global AIDS report \u2013 the urgency of now: AIDS at a crossroads. 2024. Available: https:\/\/www.unaids.org\/en\/resources\/documents\/2024\/global-aids-update-2024. Accessed June 17, 2025"},{"key":"10.1016\/j.clinme.2025.100520_bib0002","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/bcp.12403","article-title":"The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future","volume":"79","author":"Tseng","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinme.2025.100520_bib0003","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S0140-6736(00)02061-4","article-title":"Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.clinme.2025.100520_bib0004","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3018(23)00028-0","article-title":"Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies","volume":"10","author":"Trickey","year":"2023","journal-title":"Lancet HIV"},{"key":"10.1016\/j.clinme.2025.100520_bib0005","unstructured":"UK-HSA. HIV testing, PrEP, new HIV diagnoses and care outcomes for people accessing HIV services: 2024 report. 2025 Available: https:\/\/www.gov.uk\/government\/statistics\/hiv-annual-data-tables\/hiv-testing-prep-new-hiv-diagnoses-and-care-outcomes-for-people-accessing-hiv-services-2024-report. Accessed June 17, 2025"},{"key":"10.1016\/j.clinme.2025.100520_bib0006","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/infdis\/jiab420","article-title":"Incidence of cardiometabolic diseases in people with and without Human immunodeficiency virus in the United Kingdom: a population-based matched cohort study","author":"Gooden","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinme.2025.100520_bib0007","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJM199709113371102","article-title":"Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy","volume":"337","author":"Gulick","year":"1997","journal-title":"N Eng J Med"},{"key":"10.1016\/j.clinme.2025.100520_bib0008","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies","volume":"391","author":"Llibre","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.clinme.2025.100520_bib0009","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clinme.2025.100520_bib0010","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","volume":"71","author":"Van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinme.2025.100520_bib0011","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1506816","article-title":"Initiation of antiretroviral therapy in early asymptomatic HIV infection","volume":"373","year":"2015","journal-title":"N Eng J Med"},{"key":"10.1016\/j.clinme.2025.100520_bib0012","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa062360","article-title":"CD4+ Count\u2013guided interruption of antiretroviral treatment","volume":"355","year":"2006","journal-title":"N Eng J Med"},{"key":"10.1016\/j.clinme.2025.100520_bib0013","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"Prevention of HIV-1 infection with early antiretroviral therapy","volume":"365","author":"Cohen","year":"2011","journal-title":"N Eng J Med"},{"key":"10.1016\/j.clinme.2025.100520_bib0014","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1016\/S0140-6736(19)30418-0","article-title":"Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study","volume":"393","author":"Rodger","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clinme.2025.100520_bib0015","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1001\/jama.2016.5148","article-title":"Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy","volume":"316","author":"Rodger","year":"2016","journal-title":"JAMA J Am Med Assoc"},{"key":"10.1016\/j.clinme.2025.100520_bib0016","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/cid\/civ578","article-title":"No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception","volume":"61","author":"Mandelbrot","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinme.2025.100520_bib0017","doi-asserted-by":"crossref","first-page":"E590","DOI":"10.1093\/cid\/ciac703","article-title":"Update of perinatal human immunodeficiency virus type 1 transmission in France: zero transmission for 5482 mothers on continuous antiretroviral therapy from conception and with undetectable viral load at delivery","volume":"76","author":"Sibiude","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinme.2025.100520_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047260","article-title":"Disparities in the burden of HIV\/AIDS in Canada","volume":"7","author":"Hogg","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clinme.2025.100520_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002251","article-title":"Extremely high mutation rate of HIV-1 In vivo","volume":"13","author":"Cuevas","year":"2015","journal-title":"PLoS Biol"},{"key":"10.1016\/j.clinme.2025.100520_bib0020","unstructured":"Burton DR, Stanfield RL, Wilson IA Antibody vs. HIV in a clash of evolutionary titans. 2005. Available: www.pnas.orgcgidoi10.1073pnas.0505126102. Accessed June 17, 2025"},{"key":"10.1016\/j.clinme.2025.100520_bib0021","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.chom.2019.06.010","article-title":"The impact of HIV-1 drug escape on the global treatment landscape","author":"Collier","year":"2019","journal-title":"Cell Host and Microbe"},{"key":"10.1016\/j.clinme.2025.100520_bib0022","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nrg1246","article-title":"The causes and consequences of HIV evolution","author":"Rambaut","year":"2004","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.clinme.2025.100520_bib0023","doi-asserted-by":"crossref","first-page":"e620","DOI":"10.1016\/S2352-3018(20)30172-7","article-title":"Virological failure, HIV-1 drug resistance, and early mortality in adults admitted to hospital in Malawi: an observational cohort study","volume":"7","author":"Gupta-Wright","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.clinme.2025.100520_bib0024","unstructured":"University of Liverpool. Liverpool HIV drug interaction checker. [cited 27 Sep 2025]. Available: https:\/\/www.hiv-druginteractions.org\/. Accessed June 17, 2025"},{"key":"10.1016\/j.clinme.2025.100520_bib0025","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and Rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Eng J Med"},{"key":"10.1016\/j.clinme.2025.100520_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.107009","article-title":"Lenacapavir: a novel injectable HIV-1 capsid inhibitor","author":"Hitchcock","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinme.2025.100520_bib0027","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.tips.2023.05.002","article-title":"Lenacapavir (Sunlenca\u00ae) for the treatment of HIV-1","author":"Patel","year":"2023","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.clinme.2025.100520_bib0028","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","article-title":"Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection","volume":"386","author":"Segal-Maurer","year":"2022","journal-title":"N Eng J Med"},{"key":"10.1016\/j.clinme.2025.100520_bib0029","doi-asserted-by":"crossref","first-page":"6935","DOI":"10.1128\/JVI.00453-10","article-title":"Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with Anti-HIV-1 activity in infected patients","volume":"84","author":"Song","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.clinme.2025.100520_bib0030","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/AAC.00942-08","article-title":"Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults","volume":"53","author":"Jacobson","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinme.2025.100520_bib0031","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa1711460","article-title":"Phase 3 study of ibalizumab for multidrug-resistant HIV-1","volume":"379","author":"Emu","year":"2018","journal-title":"N Eng J Med"},{"key":"10.1016\/j.clinme.2025.100520_bib0032","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1016\/S2352-3018(23)00293-X","article-title":"Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study","volume":"11","author":"Eron","year":"2024","journal-title":"Lancet HIV"},{"key":"10.1016\/j.clinme.2025.100520_bib0033","series-title":"Conference on Retroviruses and Opportunistic Infections","article-title":"Efficacy and safety of switch to LENT\/TAB\/ZAB in VS PWH: week 26 primary outcome. Trial number NCT05729568: phase 2 RCT. Oral presentation 151","author":"Ogbuagu","year":"2025"},{"key":"10.1016\/j.clinme.2025.100520_bib0034","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant","year":"2010","journal-title":"N Eng J Med"},{"key":"10.1016\/j.clinme.2025.100520_bib0035","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"Baeten","year":"2012","journal-title":"N Eng J Med"},{"key":"10.1016\/j.clinme.2025.100520_bib0036","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","article-title":"Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial","volume":"387","author":"McCormack","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clinme.2025.100520_bib0037","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(20)31065-5","article-title":"Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial","volume":"396","author":"Mayer","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clinme.2025.100520_bib0038","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1016\/S2352-3018(21)00071-0","article-title":"Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Ogbuagu","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.clinme.2025.100520_bib0039","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2407001","article-title":"Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women","author":"Bekker","year":"2024","journal-title":"N Eng J Med"},{"key":"10.1016\/j.clinme.2025.100520_bib0040","article-title":"Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons","author":"Kelley","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinme.2025.100520_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(25)00405-2","article-title":"Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study","author":"Jogiraju","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.clinme.2025.100520_bib0042","unstructured":"UNAIDS. UNAIDS Botswana country data. [cited 11 Jun 2025]. Available: https:\/\/www.unaids.org\/en\/regionscountries\/countries\/botswana. Accessed June 17, 2025"},{"key":"10.1016\/j.clinme.2025.100520_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(25)00074-8","article-title":"Impact of an international HIV funding crisis on HIV infections and mortality in low-income and middle-income countries: a modelling study","author":"Brink","year":"2025","journal-title":"Lancet HIV"},{"key":"10.1016\/j.clinme.2025.100520_bib0044","unstructured":"HIV.gov. HIV.Gov PEPFAR information. [cited 11 Jun 2025]. Available: https:\/\/www.hiv.gov\/federal-response\/pepfar-global-aids\/pepfar Accessed June 17, 2025"},{"key":"10.1016\/j.clinme.2025.100520_bib0045","unstructured":"Global Burden of Disease Collaborative Network. Global Burden of disease study 2021 (GBD 2021) results. 2022 [cited 27 Sep 2025]. Available: https:\/\/vizhub.healthdata.org\/gbd-results\/ Accessed June 17, 2025"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211825002386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211825002386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T13:42:08Z","timestamp":1766151728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470211825002386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1470211825002386"],"URL":"https:\/\/doi.org\/10.1016\/j.clinme.2025.100520","relation":{},"ISSN":["1470-2118"],"issn-type":[{"value":"1470-2118","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The changing landscape of HIV epidemiology and management","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinme.2025.100520","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of Royal College of Physicians.","name":"copyright","label":"Copyright"}],"article-number":"100520"}}